Invention Grant
- Patent Title: Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
-
Application No.: US14710744Application Date: 2015-05-13
-
Publication No.: US10369161B2Publication Date: 2019-08-06
- Inventor: Hector F. DeLuca , Lori A. Plum , Margaret Clagett-Dame
- Applicant: Wisconsin Alumni Research Foundation
- Applicant Address: US WI Madison
- Assignee: Wisconsin Alumni Research Foundation
- Current Assignee: Wisconsin Alumni Research Foundation
- Current Assignee Address: US WI Madison
- Agency: Quarles & Brady LLP
- Main IPC: A61K31/593
- IPC: A61K31/593
Abstract:
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism and/or to treat and/or prevent the symptoms of primary hyperparathyroidism in as subject having or at risk for developing primary hyperparathyroidism, preferably without inducing hypercalcemia in the patient.
Public/Granted literature
- US20160184327A1 USE OF 2-METHYLENE-19-NOR-(20S)-1-ALPHA,25-DIHYDROXYVITAMIN D3 TO TREAT PRIMARY HYPERPARATHYROIDISM Public/Granted day:2016-06-30
Information query
